223 related articles for article (PubMed ID: 14990692)
1. In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists.
Stalmeijer EH; Van Rij RP; Boeser-Nunnink B; Visser JA; Naarding MA; Schols D; Schuitemaker H
J Virol; 2004 Mar; 78(6):2722-8. PubMed ID: 14990692
[TBL] [Abstract][Full Text] [Related]
2. Suppression of dualtropic human immunodeficiency virus type 1 by the CXCR4 antagonist AMD3100 is associated with efficiency of CXCR4 use and baseline virus composition.
Fransen S; Bridger G; Whitcomb JM; Toma J; Stawiski E; Parkin N; Petropoulos CJ; Huang W
Antimicrob Agents Chemother; 2008 Jul; 52(7):2608-15. PubMed ID: 18443125
[TBL] [Abstract][Full Text] [Related]
3. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4.
Esté JA; Cabrera C; Blanco J; Gutierrez A; Bridger G; Henson G; Clotet B; Schols D; De Clercq E
J Virol; 1999 Jul; 73(7):5577-85. PubMed ID: 10364306
[TBL] [Abstract][Full Text] [Related]
4. Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.
Bunnik EM; Quakkelaar ED; van Nuenen AC; Boeser-Nunnink B; Schuitemaker H
J Virol; 2007 Jan; 81(2):525-31. PubMed ID: 17079299
[TBL] [Abstract][Full Text] [Related]
5. Existence of Replication-Competent Minor Variants with Different Coreceptor Usage in Plasma from HIV-1-Infected Individuals.
Maeda Y; Takemura T; Chikata T; Kuwata T; Terasawa H; Fujimoto R; Kuse N; Akahoshi T; Murakoshi H; Tran GV; Zhang Y; Pham CH; Pham AHQ; Monde K; Sawa T; Matsushita S; Nguyen TV; Nguyen KV; Hasebe F; Yamashiro T; Takiguchi M
J Virol; 2020 Jun; 94(12):. PubMed ID: 32295903
[TBL] [Abstract][Full Text] [Related]
6. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.
Cilliers T; Nhlapo J; Coetzer M; Orlovic D; Ketas T; Olson WC; Moore JP; Trkola A; Morris L
J Virol; 2003 Apr; 77(7):4449-56. PubMed ID: 12634405
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.
De Clercq E; Schols D
Antivir Chem Chemother; 2001; 12 Suppl 1():19-31. PubMed ID: 11594685
[TBL] [Abstract][Full Text] [Related]
9. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4.
Xu Y; Tamamura H; Arakaki R; Nakashima H; Zhang X; Fujii N; Uchiyama T; Hattori T
AIDS Res Hum Retroviruses; 1999 Mar; 15(5):419-27. PubMed ID: 10195751
[TBL] [Abstract][Full Text] [Related]
10. Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection.
Mild M; Kvist A; Esbjörnsson J; Karlsson I; Fenyö EM; Medstrand P
Infect Genet Evol; 2010 Apr; 10(3):356-64. PubMed ID: 19446658
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneous spectrum of coreceptor usage among variants within a dualtropic human immunodeficiency virus type 1 primary-isolate quasispecies.
Singh A; Collman RG
J Virol; 2000 Nov; 74(21):10229-35. PubMed ID: 11024154
[TBL] [Abstract][Full Text] [Related]
12. Role of CXCR4 in cell-cell fusion and infection of monocyte-derived macrophages by primary human immunodeficiency virus type 1 (HIV-1) strains: two distinct mechanisms of HIV-1 dual tropism.
Yi Y; Isaacs SN; Williams DA; Frank I; Schols D; De Clercq E; Kolson DL; Collman RG
J Virol; 1999 Sep; 73(9):7117-25. PubMed ID: 10438797
[TBL] [Abstract][Full Text] [Related]
13. Evidence for common structural determinants of human immunodeficiency virus type 1 coreceptor activity provided through functional analysis of CCR5/CXCR4 chimeric coreceptors.
Pontow S; Ratner L
J Virol; 2001 Dec; 75(23):11503-14. PubMed ID: 11689632
[TBL] [Abstract][Full Text] [Related]
14. Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytes.
Yi Y; Shaheen F; Collman RG
J Virol; 2005 Feb; 79(3):1480-6. PubMed ID: 15650174
[TBL] [Abstract][Full Text] [Related]
15. HIV co-receptors as targets for antiviral therapy.
Schols D
Curr Top Med Chem; 2004; 4(9):883-93. PubMed ID: 15134547
[TBL] [Abstract][Full Text] [Related]
16. Development of a cell-based enzyme-linked immunosorbent assay for high-throughput screening of HIV type 1 entry inhibitors targeting the coreceptor CXCR4.
Zhao Q; Lu H; Schols D; De Clercq E; Jiang S
AIDS Res Hum Retroviruses; 2003 Nov; 19(11):947-55. PubMed ID: 14678601
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro.
Moncunill G; Armand-Ugón M; Pauls E; Clotet B; Esté JA
AIDS; 2008 Jan; 22(1):23-31. PubMed ID: 18090388
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Immune Recovery and Reduction of CXCR4-Tropic HIV-1.
Bader J; Däumer M; Schöni-Affolter F; Böni J; Gorgievski-Hrisoho M; Martinetti G; Thielen A; Klimkait T;
Clin Infect Dis; 2017 Feb; 64(3):295-300. PubMed ID: 27838645
[TBL] [Abstract][Full Text] [Related]
19. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences.
Jensen MA; Li FS; van 't Wout AB; Nickle DC; Shriner D; He HX; McLaughlin S; Shankarappa R; Margolick JB; Mullins JI
J Virol; 2003 Dec; 77(24):13376-88. PubMed ID: 14645592
[TBL] [Abstract][Full Text] [Related]
20. Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses.
Fernàndez G; Llano A; Esgleas M; Clotet B; Esté JA; Martínez MA
J Gen Virol; 2006 May; 87(Pt 5):1285-1294. PubMed ID: 16603531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
